Revista nº 798

108 / 88

108 Jose Arturo Molina Mora
Enfermedadde Tarui: revisión y perspectivas bioinformáticas
period. South Med J. 2002;95(12):1436-1440.
ncbi.nlm.nih.gov/pubmed/12597313. Accedido enero 28,
2016.
22. Nakajima H, Raben N, Hamaguchi T, Yamasaki T.
Phosphofructokinase Deficiency Past, Present
and Future. Curr Mol Med. 2002;2(2):197-212.
doi:10.2174/1566524024605734.
23. Finsterer J, Stöllberger C. Progressive mitral valve thickening
and progressive muscle cramps as manifestations
of glycogenosis VII (Tarui’s Disease). Cardiology.
2008;110(4):238-240. doi:10.1159/000112406.
24. Nichols RC, Rudolphi O, Ek B, Exelbert R, Plotz PH, Raben N.
Glycogenosis Type VII ( Tarui Disease ) in a Swedish Family :
Two Novel Mutations in Muscle Phosphofructokinase Gene (
PFK-M ) Resulting in Intron Retentions. 1996:59-65.
25. Hays AP, HallettM, Delfs J, et al. Muscle phosphofructokinase
deficiency: Abnormal polysaccharide in a case or late-onset
myopathy. Neurology. 1981;31(9):1077-1077. doi:10.1212/
WNL.31.9.1077.
26. Haller R, Vissing J. No spontaneous second wind in muscle
phosphofructokinase deficiency. Neurology. 2004;62(1):82-
86.
Accedido enero 21, 2016.
27. Di Mauro S. Muscle glycogenoses: an overview. Acta Myol.
2007;26(1):35-41.
articlerender.fcgi?artid=2949320&tool=pmcentrez&rendert
ype=abstract. Accedido enero 28, 2016.
28. Haller R, Lewis S. Glucose-induced exertional fatigue in
muscle phosphofructokinase deficiency. N Engl J Med.
1991;324(6):364-369. doi:10.1056/NEJM199102073240603.
29. Sun B, Brooks E, Koeberl D. Preclinical Development of New
Therapy for Glycogen Storage Diseases. Curr Gene Ther.
2015;15(4):338-347. doi:10.2174/15665232156661506301
32253.
30. Tsujino S, Servidei S, Tonin P, Shanske S, Azan G, DiMauro
S. Identification of three novel mutations in non-Ashkenazi
Italian patients with muscle phosphofructokinase deficiency.
Am J Hum Genet. 1994;54(5):812-819.
pubmedcentral.nih.gov/articlerender.fcgi?artid=1918246&
tool=pmcentrez&rendertype=abstract. Accedido enero 21,
2016.
31. Davidson M, Miranda AF, Bender AN, DiMauro S, Vora S.
Muscle phosphofructokinase deficiency. Biochemical and
immunological studies of phosphofructokinase isozymes
in muscle culture. J Clin Invest. 1983;72(2):545-550.
doi:10.1172/JCI111002.
32. NakajimaH,KonoN, Yamasaki T,et al. Genetic defect inmuscle
phosphofructokinase deficiency. Abnormal splicing of the
muscle phosphofructokinase gene due to a point mutation
at the 5’-splice site. J Biol Chem. 1990;265(16):9392-9395.
Accedido
enero 28, 2016.
33. Vives-Corrons J-L, Koralkova P, Grau JM, Mañú Pereira
MDM, Van Wijk R. First description of phosphofructokinase
deficiency in spain: identification of a novel homozygous
missense mutation in the PFKM gene. Front Physiol.
2013;4(December):393. doi:10.3389/fphys.2013.00393.
34. Sherman JB, Raben N, Nicastri C, et al. Common mutations
in the phosphofructokinase-M gene in Ashkenazi Jewish
patients with glycogenesis VII--and their population
frequency. Am J Hum Genet. 1994;55(2):305-313. http://
18380&tool=pmcentrez&rendertype=abstract. Accedido
enero 21, 2016.
35. Brüser A, Kirchberger J, Schöneberg T. Altered allosteric
regulation of muscle 6-phosphofructokinase causes Tarui
disease. Biochem Biophys Res Commun. 2012;427(1):133-
137. doi:10.1016/j.bbrc.2012.09.024.
36. Raben N, Sherman JB. Mutations in muscle
phosphofructokinase gene. Hum Mutat. 1995;6(1):1-6.
doi:10.1002/humu.1380060102.
37. Sola-Penna M, Da Silva D, Coelho WS, Marinho-Carvalho
MM, Zancan P. Regulation of mammalian muscle type
6-phosphofructo-1-kinase and its implication for the control
of the metabolism. IUBMB Life. 2010;62(11):791-796.
doi:10.1002/iub.393.
38. Kloos M, Bruser A, Kirchberger J, Schoneberg T, Strater N.
Crystallization and preliminary crystallographic analysis of
human muscle phosphofructokinase, the main regulator
of glycolysis. Acta Crystallogr F Struct Biol Commun.
2014;70:578-582. doi:24817713.
39. Lambeth MJ, Kushmerick MJ. A Computational Model
for Glycogenolysis in Skeletal Muscle. Ann Biomed Eng.
2002;30(6):808-827. doi:10.1114/1.1492813.